P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.
David Chiron,David Chiron,Sylvanie Surget,Sylvanie Surget,Sophie Maïga,Sophie Maïga,Régis Bataille,Philippe Moreau,Steven Le Gouill,Martine Amiot,Martine Amiot,Catherine Pellat-Deceunynck,Catherine Pellat-Deceunynck +12 more
TL;DR: The JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and longterm outcome in a cohort of 275 patients and the European LeukemiaNet (2011) critical concepts and management recommendations from European Le leukemiaNet.
Journal ArticleDOI
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.
David Chiron,Sophie Maïga,Géraldine Descamps,Philippe Moreau,Steven Le Gouill,Séverine Marionneau,Thibauld Ouiller,Jérôme Moreaux,Bernard Klein,Régis Bataille,Martine Amiot,Catherine Pellat-Deceunynck +11 more
TL;DR: The results indicate that spontaneous clonogenic growth of myeloma cells requires the expression of JAG2, and RT-PCR and flow cytometry analysis revealed that J AG2 is often expressed by CD138(+) primary cells.
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
David S. Siegel,Katja Weisel,Meletios A. Dimopoulos,Rachid Baz,Paul G. Richardson,Michel Delforge,Kevin W. Song,Jesús F. San Miguel,Philippe Moreau,Hartmut Goldschmidt,Michele Cavo,Sundar Jagannath,Xin Yu,Kevin Hong,Lars Sternas,Mohamed H. Zaki,Antonio Palumbo +16 more
TL;DR: It is demonstrated that POM’+ LoDEX is a safe and effective treatment for patients with moderate RI, and median overall response rate, progression-free survival, time to progression, and duration of response were not significantly different between RI subgroups.
Journal ArticleDOI
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
Heinz Ludwig,Philippe Moreau,Meletios A. Dimopoulos,Maria-Victoria Mateos,Martin Kaiser,Roman Hájek,Shibao Feng,Kim Cocks,Jaqueline Buchanan,Katja Weisel +9 more
TL;DR: Overall, Kd56 resulted in statistically but not clinically significant improvements in mean GHS/QoL scores versus Vd, although mean differences did not meet thresholds for clinical significance.
Journal ArticleDOI
IgM myeloma: A multicenter retrospective study of 134 patients
Jorge J. Castillo,Artur Jurczyszyn,Lucie Brozova,Edvan de Queiroz Crusoe,Jacek Czepiel,Julio Dávila,Angela Dispenzieri,Marion Eveillard,Mark A. Fiala,Irene M. Ghobrial,Alessandro Gozzetti,Joshua Gustine,Roman Hájek,Vania Hungria,Jiri Jarkovsky,David Jayabalan,Jacob P. Laubach,Barbara Lewicka,Vladimir Maisnar,Elisabet E. Manasanch,Philippe Moreau,Elizabeth A. Morgan,Hareth Nahi,Ruben Niesvizky,Claudia E. Paba-Prada,Tomas Pika,Ludek Pour,John L. Reagan,Paul G. Richardson,Jatin P. Shah,Ivan Spicka,Ravi Vij,Anna Waszczuk-Gajda,Morie A. Gertz +33 more
TL;DR: Patients with IgM myeloma present with similar characteristics and outcomes as patients with more commonMyeloma subtypes, and higher ISS score was associated with worse survival.